In Re: National Prescription Opiate Litigation

Track this case

Case overview

Case Number:

1:17-md-02804

See also:

Court:

Ohio Northern

Nature of Suit:

P.I.: Other

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Dan Aaron Polster (MDL 28

Firms

Companies

Government Agencies

Sectors & Industries:

  1. August 01, 2022

    W.Va. AG Inks $400M Deal With Drug Distributors Over Opioids

    The nation's three largest drug distributors — AmerisourceBergen, Cardinal Health and McKesson — have agreed to pay $400 million to end claims from West Virginia cities and counties that claim the pharmaceutical giants flooded the area with huge shipments of opioids and created a public nuisance, the state attorney general announced Monday.

  2. August 01, 2022

    Product Liability Cases To Watch: Midyear Review

    More trials are expected to start over claims that drug companies fueled the opioid crisis, and e-cigarette giant Juul is set to face its first case in multidistrict litigation over allegations it misrepresented the safety of its wares. Here is Law360's list of product liability cases to watch for the rest of the year.

  3. July 25, 2022

    How Reed Smith Notched A 'Sweeping' Opioid Trial Triumph

    One of America's largest distributors of prescription opioids went on trial in an epicenter of opioid abuse and emerged victorious this month by deploying a legal strategy that melded compassion and confidence, the company's lead counsel at Reed Smith LLP told Law360 in an interview.

  4. July 21, 2022

    The Rulings That Quickly Made 2022 Huge For Health Law

    A spree of remarkable rulings has already made 2022 a jaw-dropping year for health care and pharmaceutical law, where the U.S. Supreme Court reshaped abortion rights, opioid crisis prosecutions, Medicare's rulemaking powers and vital sources of hospital income. At the midyear mark, Law360 recaps the rulings and analyzes their implications.

  5. July 21, 2022

    SF, Walgreens Continue Opioid Bellwether Battle Post-Trial

    In post-trial filings Wednesday, San Francisco argued Walgreens' failure to prevent the diversion of "dangerous and highly addictive" opioids it distributed and dispensed "substantially contributed" to the city's opioid crisis, while the pharmacy giant held firm that the case lacked evidence of any harm by an opioid it sold.

  6. July 19, 2022

    Top Product Liability Cases Of 2022: Midyear Review

    Major product liability cases so far in 2022 include a ruling in West Virginia against local governments seeking relief from drug distributors for the opioid crisis and a historic settlement with gunmaker Remington to end claims brought by the families of Sandy Hook victims. Here, Law360 looks at key cases from the first half of the year.

  7. July 19, 2022

    J&J Wants Opioid Claims From NY Towns, Cities Tossed

    Johnson & Johnson wants an Ohio federal court to toss opioid claims made against the company by a host of New York municipalities, saying a change to an Empire State law bars those allegations.

  8. July 13, 2022

    Rite Aid Quietly Inks Opioid MDL Deals, Litigation Freeze

    Rite Aid Corp. has struck deals worth $10.5 million to exit three opioid-crisis cases hurtling toward bellwether trials in multidistrict litigation and to shield the pharmacy chain for 18 months from any other test cases in the MDL, according to plaintiffs counsel and an agreement marked confidential.

  9. July 13, 2022

    Walgreens Says SF Opioid Case Has 'Fatal Flaw' As Trial Ends

    Left as the lone defendant in a bellwether bench trial brought by San Francisco over the city's opioid crisis, Walgreens argued during its closing arguments Wednesday that the city didn't show any evidence its pharmacists dispensed medically inappropriate drugs — a "fatal flaw" in the case against it.

  10. July 12, 2022

    $58M Opioid Deal Cuts Allergan, Teva From SF Bellwether Trial

    San Francisco struck settlements worth almost $58 million with Allergan and Teva Pharmaceuticals on Tuesday in the sole ongoing trial over the pharmaceutical industry's role in a nationwide crisis of opioid abuse, leaving Walgreens as the last company in the closely watched showdown.